AIMM Therapeutics in Strategic Partnership With Cosmo Pharmaceuticals S.p.A. to Combine Cosmo's Extended Release Technology & AIMM's High Quality Antibodies to Successfully Combat Gastrointestinal Disease

Published: Dec 19, 2012

AMSTERDAM--(BUSINESS WIRE)--AIMM Therapeutics, a therapeutic antibody company, today announced a strategic partnership with Cosmo Pharmaceuticals (SIX:COPN), Milan, Italy, to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma. Under the agreement, Cosmo Pharmaceuticals will formulate novel human monoclonal antibodies generated by AIMM Therapeutics in an extended release form exploiting its proprietary MMX® technology. No financial details were disclosed. Jan de Vries, CEO of AIMM Therapeutics, said, “The strong preclinical in vivo data generated by Cosmo using its MMX technology show the tremendous potential of oral antibody delivery for gastrointestinal diseases. We expect that the combination of Cosmo’s MMX technology with AIMM’s antibodies will allow us to build a unique portfolio of products with a compelling competitive advantage in gastrointestinal disease.” Mauro Ajani, Chairman and CEO of Cosmo Pharmaceuticals, said, “Access to AIMM’s proprietary high quality antibodies through our partnership will enable us to rapidly advance the oral delivery of diagnostic and therapeutic antibodies into clinical studies.”

Back to news